UBS analyst Ashwani Verma maintained a Buy rating on Harmony Biosciences Holdings today and set a price target of $43.00. The company’s shares closed yesterday at $26.36.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Verma is a 3-star analyst with an average return of 5.2% and a 50.00% success rate. Verma covers the Healthcare sector, focusing on stocks such as United Therapeutics, ACADIA Pharmaceuticals, and Exelixis.
Harmony Biosciences Holdings has an analyst consensus of Strong Buy, with a price target consensus of $44.56.
HRMY market cap is currently $1.53B and has a P/E ratio of 8.50.
Read More on HRMY:
Disclaimer & DisclosureReport an Issue
- Harmony Biosciences price target lowered to $36 from $54 at Deutsche Bank
- Harmony Biosciences price target lowered to $35 from $50 at Mizuho
- Harmony Biosciences price target lowered to $55 from $70 at H.C. Wainwright
- Sell Rating for Harmony Biosciences: Setbacks in R&D and Uncertain Pipeline Outlook
- Harmony Biosciences Phase 3 Study Misses Endpoint
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/Amazon%20-%20Image%20by%20bluestork%20via%20Shutterstock.jpg)
/Apple%20Inc%20logo%20on%20Apple%20store-by%20PhillDanze%20via%20iStock.jpg)
/A%20Palantir%20sign%20displayed%20on%20an%20office%20building%20by%20Poetra_RH%20via%20Shutterstock.jpg)
